img

Global Cancer Antibody Drug Conjugates Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Cancer Antibody Drug Conjugates Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Cancer Antibody Drug Conjugates report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Cancer Antibody Drug Conjugates market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospitals and Clinics are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Cancer Antibody Drug Conjugates industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Cancer Antibody Drug Conjugates key manufacturers include Novartis, Merck, Roche, AbbVie, UCB, Bristol-Myers Squibb, Stem CentRx, Biogen Idec and Nordic Nanovector, etc. Novartis, Merck, Roche are top 3 players and held % sales share in total in 2022.
Cancer Antibody Drug Conjugates can be divided into First & Second Generation ADCs and Third Generation ADCs, etc. First & Second Generation ADCs is the mainstream product in the market, accounting for % sales share globally in 2022.
Cancer Antibody Drug Conjugates is widely used in various fields, such as Hospitals, Clinics and Others,, etc. Hospitals provides greatest supports to the Cancer Antibody Drug Conjugates industry development. In 2022, global % sales of Cancer Antibody Drug Conjugates went into Hospitals filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Cancer Antibody Drug Conjugates market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Novartis
Merck
Roche
AbbVie
UCB
Bristol-Myers Squibb
Stem CentRx
Biogen Idec
Nordic Nanovector
Millennium
Biotest AG
PDL BioPharma
Progenics Pharmaceuticals
Seattle Genetics
Viventia Biotechnologies
AbGenomics Corporation
Helix BioPharma
Segment by Type
First & Second Generation ADCs
Third Generation ADCs

Segment by Application


Hospitals
Clinics
Others

Segment by Region


North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Cancer Antibody Drug Conjugates market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Cancer Antibody Drug Conjugates, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Cancer Antibody Drug Conjugates industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Cancer Antibody Drug Conjugates in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Cancer Antibody Drug Conjugates introduction, etc. Cancer Antibody Drug Conjugates Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Cancer Antibody Drug Conjugates market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.

Table of Content

1 Cancer Antibody Drug Conjugates Market Overview
1.1 Cancer Antibody Drug Conjugates Product Overview
1.2 Cancer Antibody Drug Conjugates Market Segment by Type
1.2.1 First & Second Generation ADCs
1.2.2 Third Generation ADCs
1.3 Global Cancer Antibody Drug Conjugates Market Size by Type
1.3.1 Global Cancer Antibody Drug Conjugates Market Size Overview by Type (2018-2034)
1.3.2 Global Cancer Antibody Drug Conjugates Historic Market Size Review by Type (2018-2024)
1.3.3 Global Cancer Antibody Drug Conjugates Forecasted Market Size by Type (2024-2034)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Cancer Antibody Drug Conjugates Sales Breakdown by Type (2018-2024)
1.4.2 Europe Cancer Antibody Drug Conjugates Sales Breakdown by Type (2018-2024)
1.4.3 Asia-Pacific Cancer Antibody Drug Conjugates Sales Breakdown by Type (2018-2024)
1.4.4 Latin America Cancer Antibody Drug Conjugates Sales Breakdown by Type (2018-2024)
1.4.5 Middle East and Africa Cancer Antibody Drug Conjugates Sales Breakdown by Type (2018-2024)
2 Global Cancer Antibody Drug Conjugates Market Competition by Company
2.1 Global Top Players by Cancer Antibody Drug Conjugates Sales (2018-2024)
2.2 Global Top Players by Cancer Antibody Drug Conjugates Revenue (2018-2024)
2.3 Global Top Players by Cancer Antibody Drug Conjugates Price (2018-2024)
2.4 Global Top Manufacturers Cancer Antibody Drug Conjugates Manufacturing Base Distribution, Sales Area, Product Type
2.5 Cancer Antibody Drug Conjugates Market Competitive Situation and Trends
2.5.1 Cancer Antibody Drug Conjugates Market Concentration Rate (2018-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Cancer Antibody Drug Conjugates Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Cancer Antibody Drug Conjugates as of 2022)
2.7 Date of Key Manufacturers Enter into Cancer Antibody Drug Conjugates Market
2.8 Key Manufacturers Cancer Antibody Drug Conjugates Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Cancer Antibody Drug Conjugates Status and Outlook by Region
3.1 Global Cancer Antibody Drug Conjugates Market Size and CAGR by Region: 2018 VS 2022 VS 2034
3.2 Global Cancer Antibody Drug Conjugates Historic Market Size by Region
3.2.1 Global Cancer Antibody Drug Conjugates Sales in Volume by Region (2018-2024)
3.2.2 Global Cancer Antibody Drug Conjugates Sales in Value by Region (2018-2024)
3.2.3 Global Cancer Antibody Drug Conjugates Sales (Volume & Value) Price and Gross Margin (2018-2024)
3.3 Global Cancer Antibody Drug Conjugates Forecasted Market Size by Region
3.3.1 Global Cancer Antibody Drug Conjugates Sales in Volume by Region (2024-2034)
3.3.2 Global Cancer Antibody Drug Conjugates Sales in Value by Region (2024-2034)
3.3.3 Global Cancer Antibody Drug Conjugates Sales (Volume & Value), Price and Gross Margin (2024-2034)
4 Global Cancer Antibody Drug Conjugates by Application
4.1 Cancer Antibody Drug Conjugates Market Segment by Application
4.1.1 Hospitals
4.1.2 Clinics
4.1.3 Others
4.2 Global Cancer Antibody Drug Conjugates Market Size by Application
4.2.1 Global Cancer Antibody Drug Conjugates Market Size Overview by Application (2018-2034)
4.2.2 Global Cancer Antibody Drug Conjugates Historic Market Size Review by Application (2018-2024)
4.2.3 Global Cancer Antibody Drug Conjugates Forecasted Market Size by Application (2024-2034)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Cancer Antibody Drug Conjugates Sales Breakdown by Application (2018-2024)
4.3.2 Europe Cancer Antibody Drug Conjugates Sales Breakdown by Application (2018-2024)
4.3.3 Asia-Pacific Cancer Antibody Drug Conjugates Sales Breakdown by Application (2018-2024)
4.3.4 Latin America Cancer Antibody Drug Conjugates Sales Breakdown by Application (2018-2024)
4.3.5 Middle East and Africa Cancer Antibody Drug Conjugates Sales Breakdown by Application (2018-2024)
5 North America Cancer Antibody Drug Conjugates by Country
5.1 North America Cancer Antibody Drug Conjugates Historic Market Size by Country
5.1.1 North America Cancer Antibody Drug Conjugates Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
5.1.2 North America Cancer Antibody Drug Conjugates Sales in Volume by Country (2018-2024)
5.1.3 North America Cancer Antibody Drug Conjugates Sales in Value by Country (2018-2024)
5.2 North America Cancer Antibody Drug Conjugates Forecasted Market Size by Country
5.2.1 North America Cancer Antibody Drug Conjugates Sales in Volume by Country (2024-2034)
5.2.2 North America Cancer Antibody Drug Conjugates Sales in Value by Country (2024-2034)
6 Europe Cancer Antibody Drug Conjugates by Country
6.1 Europe Cancer Antibody Drug Conjugates Historic Market Size by Country
6.1.1 Europe Cancer Antibody Drug Conjugates Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
6.1.2 Europe Cancer Antibody Drug Conjugates Sales in Volume by Country (2018-2024)
6.1.3 Europe Cancer Antibody Drug Conjugates Sales in Value by Country (2018-2024)
6.2 Europe Cancer Antibody Drug Conjugates Forecasted Market Size by Country
6.2.1 Europe Cancer Antibody Drug Conjugates Sales in Volume by Country (2024-2034)
6.2.2 Europe Cancer Antibody Drug Conjugates Sales in Value by Country (2024-2034)
7 Asia-Pacific Cancer Antibody Drug Conjugates by Region
7.1 Asia-Pacific Cancer Antibody Drug Conjugates Historic Market Size by Region
7.1.1 Asia-Pacific Cancer Antibody Drug Conjugates Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
7.1.2 Asia-Pacific Cancer Antibody Drug Conjugates Sales in Volume by Region (2018-2024)
7.1.3 Asia-Pacific Cancer Antibody Drug Conjugates Sales in Value by Region (2018-2024)
7.2 Asia-Pacific Cancer Antibody Drug Conjugates Forecasted Market Size by Region
7.2.1 Asia-Pacific Cancer Antibody Drug Conjugates Sales in Volume by Region (2024-2034)
7.2.2 Asia-Pacific Cancer Antibody Drug Conjugates Sales in Value by Region (2024-2034)
8 Latin America Cancer Antibody Drug Conjugates by Country
8.1 Latin America Cancer Antibody Drug Conjugates Historic Market Size by Country
8.1.1 Latin America Cancer Antibody Drug Conjugates Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
8.1.2 Latin America Cancer Antibody Drug Conjugates Sales in Volume by Country (2018-2024)
8.1.3 Latin America Cancer Antibody Drug Conjugates Sales in Value by Country (2018-2024)
8.2 Latin America Cancer Antibody Drug Conjugates Forecasted Market Size by Country
8.2.1 Latin America Cancer Antibody Drug Conjugates Sales in Volume by Country (2024-2034)
8.2.2 Latin America Cancer Antibody Drug Conjugates Sales in Value by Country (2024-2034)
9 Middle East and Africa Cancer Antibody Drug Conjugates by Country
9.1 Middle East and Africa Cancer Antibody Drug Conjugates Historic Market Size by Country
9.1.1 Middle East and Africa Cancer Antibody Drug Conjugates Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
9.1.2 Middle East and Africa Cancer Antibody Drug Conjugates Sales in Volume by Country (2018-2024)
9.1.3 Middle East and Africa Cancer Antibody Drug Conjugates Sales in Value by Country (2018-2024)
9.2 Middle East and Africa Cancer Antibody Drug Conjugates Forecasted Market Size by Country
9.2.1 Middle East and Africa Cancer Antibody Drug Conjugates Sales in Volume by Country (2024-2034)
9.2.2 Middle East and Africa Cancer Antibody Drug Conjugates Sales in Value by Country (2024-2034)
10 Company Profiles
10.1 Novartis
10.1.1 Novartis Company Information
10.1.2 Novartis Introduction and Business Overview
10.1.3 Novartis Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2018-2024)
10.1.4 Novartis Cancer Antibody Drug Conjugates Products Offered
10.1.5 Novartis Recent Development
10.2 Merck
10.2.1 Merck Company Information
10.2.2 Merck Introduction and Business Overview
10.2.3 Merck Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2018-2024)
10.2.4 Merck Cancer Antibody Drug Conjugates Products Offered
10.2.5 Merck Recent Development
10.3 Roche
10.3.1 Roche Company Information
10.3.2 Roche Introduction and Business Overview
10.3.3 Roche Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2018-2024)
10.3.4 Roche Cancer Antibody Drug Conjugates Products Offered
10.3.5 Roche Recent Development
10.4 AbbVie
10.4.1 AbbVie Company Information
10.4.2 AbbVie Introduction and Business Overview
10.4.3 AbbVie Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2018-2024)
10.4.4 AbbVie Cancer Antibody Drug Conjugates Products Offered
10.4.5 AbbVie Recent Development
10.5 UCB
10.5.1 UCB Company Information
10.5.2 UCB Introduction and Business Overview
10.5.3 UCB Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2018-2024)
10.5.4 UCB Cancer Antibody Drug Conjugates Products Offered
10.5.5 UCB Recent Development
10.6 Bristol-Myers Squibb
10.6.1 Bristol-Myers Squibb Company Information
10.6.2 Bristol-Myers Squibb Introduction and Business Overview
10.6.3 Bristol-Myers Squibb Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2018-2024)
10.6.4 Bristol-Myers Squibb Cancer Antibody Drug Conjugates Products Offered
10.6.5 Bristol-Myers Squibb Recent Development
10.7 Stem CentRx
10.7.1 Stem CentRx Company Information
10.7.2 Stem CentRx Introduction and Business Overview
10.7.3 Stem CentRx Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2018-2024)
10.7.4 Stem CentRx Cancer Antibody Drug Conjugates Products Offered
10.7.5 Stem CentRx Recent Development
10.8 Biogen Idec
10.8.1 Biogen Idec Company Information
10.8.2 Biogen Idec Introduction and Business Overview
10.8.3 Biogen Idec Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2018-2024)
10.8.4 Biogen Idec Cancer Antibody Drug Conjugates Products Offered
10.8.5 Biogen Idec Recent Development
10.9 Nordic Nanovector
10.9.1 Nordic Nanovector Company Information
10.9.2 Nordic Nanovector Introduction and Business Overview
10.9.3 Nordic Nanovector Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2018-2024)
10.9.4 Nordic Nanovector Cancer Antibody Drug Conjugates Products Offered
10.9.5 Nordic Nanovector Recent Development
10.10 Millennium
10.10.1 Millennium Company Information
10.10.2 Millennium Introduction and Business Overview
10.10.3 Millennium Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2018-2024)
10.10.4 Millennium Cancer Antibody Drug Conjugates Products Offered
10.10.5 Millennium Recent Development
10.11 Biotest AG
10.11.1 Biotest AG Company Information
10.11.2 Biotest AG Introduction and Business Overview
10.11.3 Biotest AG Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2018-2024)
10.11.4 Biotest AG Cancer Antibody Drug Conjugates Products Offered
10.11.5 Biotest AG Recent Development
10.12 PDL BioPharma
10.12.1 PDL BioPharma Company Information
10.12.2 PDL BioPharma Introduction and Business Overview
10.12.3 PDL BioPharma Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2018-2024)
10.12.4 PDL BioPharma Cancer Antibody Drug Conjugates Products Offered
10.12.5 PDL BioPharma Recent Development
10.13 Progenics Pharmaceuticals
10.13.1 Progenics Pharmaceuticals Company Information
10.13.2 Progenics Pharmaceuticals Introduction and Business Overview
10.13.3 Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2018-2024)
10.13.4 Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Products Offered
10.13.5 Progenics Pharmaceuticals Recent Development
10.14 Seattle Genetics
10.14.1 Seattle Genetics Company Information
10.14.2 Seattle Genetics Introduction and Business Overview
10.14.3 Seattle Genetics Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2018-2024)
10.14.4 Seattle Genetics Cancer Antibody Drug Conjugates Products Offered
10.14.5 Seattle Genetics Recent Development
10.15 Viventia Biotechnologies
10.15.1 Viventia Biotechnologies Company Information
10.15.2 Viventia Biotechnologies Introduction and Business Overview
10.15.3 Viventia Biotechnologies Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2018-2024)
10.15.4 Viventia Biotechnologies Cancer Antibody Drug Conjugates Products Offered
10.15.5 Viventia Biotechnologies Recent Development
10.16 AbGenomics Corporation
10.16.1 AbGenomics Corporation Company Information
10.16.2 AbGenomics Corporation Introduction and Business Overview
10.16.3 AbGenomics Corporation Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2018-2024)
10.16.4 AbGenomics Corporation Cancer Antibody Drug Conjugates Products Offered
10.16.5 AbGenomics Corporation Recent Development
10.17 Helix BioPharma
10.17.1 Helix BioPharma Company Information
10.17.2 Helix BioPharma Introduction and Business Overview
10.17.3 Helix BioPharma Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2018-2024)
10.17.4 Helix BioPharma Cancer Antibody Drug Conjugates Products Offered
10.17.5 Helix BioPharma Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Cancer Antibody Drug Conjugates Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Cancer Antibody Drug Conjugates Industrial Chain Analysis
11.4 Cancer Antibody Drug Conjugates Market Dynamics
11.4.1 Cancer Antibody Drug Conjugates Industry Trends
11.4.2 Cancer Antibody Drug Conjugates Market Drivers
11.4.3 Cancer Antibody Drug Conjugates Market Challenges
11.4.4 Cancer Antibody Drug Conjugates Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Cancer Antibody Drug Conjugates Distributors
12.3 Cancer Antibody Drug Conjugates Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of First & Second Generation ADCs
Table 2. Major Company of Third Generation ADCs
Table 3. Global Cancer Antibody Drug Conjugates Sales by Type 2018 VS 2022 VS 2034 (US$ Million)
Table 4. Global Cancer Antibody Drug Conjugates Sales by Type (2018-2024) & (K Dose)
Table 5. Global Cancer Antibody Drug Conjugates Sales Market Share in Volume by Type (2018-2024)
Table 6. Global Cancer Antibody Drug Conjugates Sales by Type (2018-2024) & (US& Million)
Table 7. Global Cancer Antibody Drug Conjugates Market Share in Value by Type (2018-2024)
Table 8. Global Cancer Antibody Drug Conjugates Price by Type (2018-2024) & (USD/Dose)
Table 9. Global Cancer Antibody Drug Conjugates Sales by Type (2024-2034) & (K Dose)
Table 10. Global Cancer Antibody Drug Conjugates Sales Market Share in Volume by Type (2024-2034)
Table 11. Global Cancer Antibody Drug Conjugates Sales by Type (2024-2034) & (US$ Million)
Table 12. Global Cancer Antibody Drug Conjugates Sales Market Share in Value by Type (2024-2034)
Table 13. Global Cancer Antibody Drug Conjugates Price by Type (2024-2034) & (USD/Dose)
Table 14. North America Cancer Antibody Drug Conjugates Sales by Type (2018-2024) & (K Dose)
Table 15. North America Cancer Antibody Drug Conjugates Sales by Type (2018-2024) & (US$ Million)
Table 16. Europe Cancer Antibody Drug Conjugates Sales (K Dose) by Type (2018-2024)
Table 17. Europe Cancer Antibody Drug Conjugates Sales by Type (2018-2024) & (US$ Million)
Table 18. Asia-Pacific Cancer Antibody Drug Conjugates Sales (K Dose) by Type (2018-2024)
Table 19. Asia-Pacific Cancer Antibody Drug Conjugates Sales by Type (2018-2024) & (US$ Million)
Table 20. Latin America Cancer Antibody Drug Conjugates Sales (K Dose) by Type (2018-2024)
Table 21. Latin America Cancer Antibody Drug Conjugates Sales by Type (2018-2024) & (US$ Million)
Table 22. Middle East and Africa Cancer Antibody Drug Conjugates Sales (K Dose) by Type (2018-2024)
Table 23. Middle East and Africa Cancer Antibody Drug Conjugates Sales by Type (2018-2024) & (US$ Million)
Table 24. Global Cancer Antibody Drug Conjugates Sales by Company (2018-2024) & (K Dose)
Table 25. Global Cancer Antibody Drug Conjugates Sales Share by Company (2018-2024)
Table 26. Global Cancer Antibody Drug Conjugates Revenue by Company (2018-2024) & (US$ Million)
Table 27. Global Cancer Antibody Drug Conjugates Revenue Share by Company (2018-2024)
Table 28. Global Market Cancer Antibody Drug Conjugates Price by Company (2018-2024) & (USD/Dose)
Table 29. Global Cancer Antibody Drug Conjugates Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 30. Global Cancer Antibody Drug Conjugates Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 31. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Cancer Antibody Drug Conjugates as of 2022)
Table 32. Date of Key Manufacturers Enter into Cancer Antibody Drug Conjugates Market
Table 33. Key Manufacturers Cancer Antibody Drug Conjugates Product Type
Table 34. Mergers & Acquisitions, Expansion Plans
Table 35. Global Cancer Antibody Drug Conjugates Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2034
Table 36. Global Cancer Antibody Drug Conjugates Sales by Region (2018-2024) & (K Dose)
Table 37. Global Cancer Antibody Drug Conjugates Sales Market Share in Volume by Region (2018-2024)
Table 38. Global Cancer Antibody Drug Conjugates Sales by Region (2018-2024) & (US$ Million)
Table 39. Global Cancer Antibody Drug Conjugates Sales Market Share in Value by Region (2018-2024)
Table 40. Global Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2024)
Table 41. Global Cancer Antibody Drug Conjugates Sales by Region (2024-2034) & (K Dose)
Table 42. Global Cancer Antibody Drug Conjugates Sales Market Share in Volume by Region (2024-2034)
Table 43. Global Cancer Antibody Drug Conjugates Sales by Region (2024-2034) & (US$ Million)
Table 44. Global Cancer Antibody Drug Conjugates Sales Market Share in Value by Region (2024-2034)
Table 45. Global Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2024-2034)
Table 46. Global Cancer Antibody Drug Conjugates Sales by Application: 2018 VS 2022 VS 2034 (US$ Million)
Table 47. Global Cancer Antibody Drug Conjugates Sales by Application (2018-2024) & (K Dose)
Table 48. Global Cancer Antibody Drug Conjugates Sales Market Share in Volume by Application (2018-2024)
Table 49. Global Cancer Antibody Drug Conjugates Sales by Application (2018-2024) & (US$ Million)
Table 50. Global Cancer Antibody Drug Conjugates Sales Market Share in Value by Application (2018-2024)
Table 51. Global Cancer Antibody Drug Conjugates Price by Application (2018-2024) & (USD/Dose)
Table 52. Global Cancer Antibody Drug Conjugates Sales by Application (2024-2034) & (K Dose)
Table 53. Global Cancer Antibody Drug Conjugates Sales Market Share in Volume by Application (2024-2034)
Table 54. Global Cancer Antibody Drug Conjugates Sales by Application (2024-2034) & (US$ Million)
Table 55. Global Cancer Antibody Drug Conjugates Sales Market Share in Value by Application (2024-2034)
Table 56. Global Cancer Antibody Drug Conjugates Price by Application (2024-2034) & (USD/Dose)
Table 57. North America Cancer Antibody Drug Conjugates Sales by Application (2018-2024) (K Dose)
Table 58. North America Cancer Antibody Drug Conjugates Sales by Application (2018-2024) & (US$ Million)
Table 59. Europe Cancer Antibody Drug Conjugates Sales by Application (2018-2024) (K Dose)
Table 60. Europe Cancer Antibody Drug Conjugates Sales by Application (2018-2024) & (US$ Million)
Table 61. Asia-Pacific Cancer Antibody Drug Conjugates Sales by Application (2018-2024) (K Dose)
Table 62. Asia-Pacific Cancer Antibody Drug Conjugates Sales by Application (2018-2024) & (US$ Million)
Table 63. Latin America Cancer Antibody Drug Conjugates Sales by Application (2018-2024) (K Dose)
Table 64. Latin America Cancer Antibody Drug Conjugates Sales by Application (2018-2024) & (US$ Million)
Table 65. Middle East and Africa Cancer Antibody Drug Conjugates Sales by Application (2018-2024) (K Dose)
Table 66. Middle East and Africa Cancer Antibody Drug Conjugates Sales by Application (2018-2024) & (US$ Million)
Table 67. North America Cancer Antibody Drug Conjugates Sales by Country (2018-2024) & (K Dose)
Table 68. North America Cancer Antibody Drug Conjugates Sales Market Share in Volume by Country (2018-2024)
Table 69. North America Cancer Antibody Drug Conjugates Sales by Country (2018-2024) & (US$ Million)
Table 70. North America Cancer Antibody Drug Conjugates Sales Market Share in Value by Country (2018-2024)
Table 71. North America Cancer Antibody Drug Conjugates Sales by Country (2024-2034) & (K Dose)
Table 72. North America Cancer Antibody Drug Conjugates Sales Market Share in Volume by Country (2024-2034)
Table 73. North America Cancer Antibody Drug Conjugates Sales by Country (2024-2034) & (US$ Million)
Table 74. North America Cancer Antibody Drug Conjugates Sales Market Share in Value by Country (2024-2034)
Table 75. Europe Cancer Antibody Drug Conjugates Sales by Country (2018-2024) & (K Dose)
Table 76. Europe Cancer Antibody Drug Conjugates Sales Market Share in Volume by Country (2018-2024)
Table 77. Europe Cancer Antibody Drug Conjugates Sales by Country (2018-2024) & (US$ Million)
Table 78. Europe Cancer Antibody Drug Conjugates Sales Market Share in Value by Country (2018-2024)
Table 79. Europe Cancer Antibody Drug Conjugates Sales by Country (2024-2034) & (K Dose)
Table 80. Europe Cancer Antibody Drug Conjugates Sales Market Share in Volume by Country (2024-2034)
Table 81. Europe Cancer Antibody Drug Conjugates Sales by Country (2024-2034) & (US$ Million)
Table 82. Europe Cancer Antibody Drug Conjugates Sales Market Share in Value by Country (2024-2034)
Table 83. Asia-Pacific Cancer Antibody Drug Conjugates Sales by Region (2018-2024) & (K Dose)
Table 84. Asia-Pacific Cancer Antibody Drug Conjugates Sales Market Share in Volume by Region (2018-2024)
Table 85. Asia-Pacific Cancer Antibody Drug Conjugates Sales by Region (2018-2024) & (US$ Million)
Table 86. Asia-Pacific Cancer Antibody Drug Conjugates Sales Market Share in Value by Region (2018-2024)
Table 87. Asia-Pacific Cancer Antibody Drug Conjugates Sales by Region (2024-2034) & (K Dose)
Table 88. Asia-Pacific Cancer Antibody Drug Conjugates Sales Market Share in Volume by Region (2024-2034)
Table 89. Asia-Pacific Cancer Antibody Drug Conjugates Sales by Region (2024-2034) & (US$ Million)
Table 90. Asia-Pacific Cancer Antibody Drug Conjugates Sales Market Share in Value by Region (2024-2034)
Table 91. Latin America Cancer Antibody Drug Conjugates Sales by Country (2018-2024) & (K Dose)
Table 92. Latin America Cancer Antibody Drug Conjugates Sales Market Share in Volume by Country (2018-2024)
Table 93. Latin America Cancer Antibody Drug Conjugates Sales by Country (2018-2024) & (US$ Million)
Table 94. Latin America Cancer Antibody Drug Conjugates Sales Market Share in Value by Country (2018-2024)
Table 95. Latin America Cancer Antibody Drug Conjugates Sales by Country (2024-2034) & (K Dose)
Table 96. Latin America Cancer Antibody Drug Conjugates Sales Market Share in Volume by Country (2024-2034)
Table 97. Latin America Cancer Antibody Drug Conjugates Sales by Country (2024-2034) & (US$ Million)
Table 98. Latin America Cancer Antibody Drug Conjugates Sales Market Share in Value by Country (2024-2034)
Table 99. Middle East and Africa Cancer Antibody Drug Conjugates Sales by Country (2018-2024) & (K Dose)
Table 100. Middle East and Africa Cancer Antibody Drug Conjugates Sales Market Share in Volume by Country (2018-2024)
Table 101. Middle East and Africa Cancer Antibody Drug Conjugates Sales by Country (2018-2024) & (US$ Million)
Table 102. Middle East and Africa Cancer Antibody Drug Conjugates Sales Market Share in Value by Country (2018-2024)
Table 103. Middle East and Africa Cancer Antibody Drug Conjugates Sales by Country (2024-2034) & (K Dose)
Table 104. Middle East and Africa Cancer Antibody Drug Conjugates Sales Market Share in Volume by Country (2024-2034)
Table 105. Middle East and Africa Cancer Antibody Drug Conjugates Sales by Country (2024-2034) & (US$ Million)
Table 106. Middle East and Africa Cancer Antibody Drug Conjugates Sales Market Share in Value by Country (2024-2034)
Table 107. Novartis Company Information
Table 108. Novartis Introduction and Business Overview
Table 109. Novartis Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2024)
Table 110. Novartis Cancer Antibody Drug Conjugates Product
Table 111. Novartis Recent Development
Table 112. Merck Company Information
Table 113. Merck Introduction and Business Overview
Table 114. Merck Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2024)
Table 115. Merck Cancer Antibody Drug Conjugates Product
Table 116. Merck Recent Development
Table 117. Roche Company Information
Table 118. Roche Introduction and Business Overview
Table 119. Roche Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2024)
Table 120. Roche Cancer Antibody Drug Conjugates Product
Table 121. Roche Recent Development
Table 122. AbbVie Company Information
Table 123. AbbVie Introduction and Business Overview
Table 124. AbbVie Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2024)
Table 125. AbbVie Cancer Antibody Drug Conjugates Product
Table 126. AbbVie Recent Development
Table 127. UCB Company Information
Table 128. UCB Introduction and Business Overview
Table 129. UCB Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2024)
Table 130. UCB Cancer Antibody Drug Conjugates Product
Table 131. UCB Recent Development
Table 132. Bristol-Myers Squibb Company Information
Table 133. Bristol-Myers Squibb Introduction and Business Overview
Table 134. Bristol-Myers Squibb Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2024)
Table 135. Bristol-Myers Squibb Cancer Antibody Drug Conjugates Product
Table 136. Bristol-Myers Squibb Recent Development
Table 137. Stem CentRx Company Information
Table 138. Stem CentRx Introduction and Business Overview
Table 139. Stem CentRx Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2024)
Table 140. Stem CentRx Cancer Antibody Drug Conjugates Product
Table 141. Stem CentRx Recent Development
Table 142. Biogen Idec Company Information
Table 143. Biogen Idec Introduction and Business Overview
Table 144. Biogen Idec Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2024)
Table 145. Biogen Idec Cancer Antibody Drug Conjugates Product
Table 146. Biogen Idec Recent Development
Table 147. Nordic Nanovector Company Information
Table 148. Nordic Nanovector Introduction and Business Overview
Table 149. Nordic Nanovector Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2024)
Table 150. Nordic Nanovector Cancer Antibody Drug Conjugates Product
Table 151. Nordic Nanovector Recent Development
Table 152. Millennium Company Information
Table 153. Millennium Introduction and Business Overview
Table 154. Millennium Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2024)
Table 155. Millennium Cancer Antibody Drug Conjugates Product
Table 156. Millennium Recent Development
Table 157. Biotest AG Company Information
Table 158. Biotest AG Introduction and Business Overview
Table 159. Biotest AG Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2024)
Table 160. Biotest AG Cancer Antibody Drug Conjugates Product
Table 161. Biotest AG Recent Development
Table 162. PDL BioPharma Company Information
Table 163. PDL BioPharma Introduction and Business Overview
Table 164. PDL BioPharma Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2024)
Table 165. PDL BioPharma Cancer Antibody Drug Conjugates Product
Table 166. PDL BioPharma Recent Development
Table 167. Progenics Pharmaceuticals Company Information
Table 168. Progenics Pharmaceuticals Introduction and Business Overview
Table 169. Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2024)
Table 170. Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Product
Table 171. Progenics Pharmaceuticals Recent Development
Table 172. Seattle Genetics Company Information
Table 173. Seattle Genetics Introduction and Business Overview
Table 174. Seattle Genetics Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2024)
Table 175. Seattle Genetics Cancer Antibody Drug Conjugates Product
Table 176. Seattle Genetics Recent Development
Table 177. Viventia Biotechnologies Company Information
Table 178. Viventia Biotechnologies Introduction and Business Overview
Table 179. Viventia Biotechnologies Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2024)
Table 180. Viventia Biotechnologies Cancer Antibody Drug Conjugates Product
Table 181. Viventia Biotechnologies Recent Development
Table 182. AbGenomics Corporation Company Information
Table 183. AbGenomics Corporation Introduction and Business Overview
Table 184. AbGenomics Corporation Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2024)
Table 185. AbGenomics Corporation Cancer Antibody Drug Conjugates Product
Table 186. AbGenomics Corporation Recent Development
Table 187. Helix BioPharma Company Information
Table 188. Helix BioPharma Introduction and Business Overview
Table 189. Helix BioPharma Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2024)
Table 190. Helix BioPharma Cancer Antibody Drug Conjugates Product
Table 191. Helix BioPharma Recent Development
Table 192. Key Raw Materials Lists
Table 193. Raw Materials Key Suppliers Lists
Table 194. Cancer Antibody Drug Conjugates Market Trends
Table 195. Cancer Antibody Drug Conjugates Market Drivers
Table 196. Cancer Antibody Drug Conjugates Market Challenges
Table 197. Cancer Antibody Drug Conjugates Market Restraints
Table 198. Cancer Antibody Drug Conjugates Distributors List
Table 199. Cancer Antibody Drug Conjugates Downstream Customers
Table 200. Research Programs/Design for This Report
Table 201. Key Data Information from Secondary Sources
Table 202. Key Data Information from Primary Sources
List of Figures
Figure 1. Cancer Antibody Drug Conjugates Product Picture
Figure 2. Global Cancer Antibody Drug Conjugates Market Size, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Cancer Antibody Drug Conjugates Market Size Status and Outlook (2018-2034) & (US$ Million)
Figure 4. Global Cancer Antibody Drug Conjugates Sales Status and Outlook (2018-2034) & (K Dose)
Figure 5. Product Picture of First & Second Generation ADCs
Figure 6. Global First & Second Generation ADCs Sales YoY Growth (2018-2034) & (K Dose)
Figure 7. Product Picture of Third Generation ADCs
Figure 8. Global Third Generation ADCs Sales YoY Growth (2018-2034) & (K Dose)
Figure 9. Global Cancer Antibody Drug Conjugates Sales by Type (2018-2034) & (US$ Million)
Figure 10. Global Cancer Antibody Drug Conjugates Sales Market Share by Type in 2022 & 2034
Figure 11. North America Cancer Antibody Drug Conjugates Sales Market Share in Volume by Type in 2022
Figure 12. North America Cancer Antibody Drug Conjugates Sales Market Share in Value by Type in 2022
Figure 13. Europe Cancer Antibody Drug Conjugates Sales Market Share in Volume by Type in 2022
Figure 14. Europe Cancer Antibody Drug Conjugates Sales Market Share in Value by Type in 2022
Figure 15. Asia-Pacific Cancer Antibody Drug Conjugates Sales Market Share in Volume by Type in 2022
Figure 16. Asia-Pacific Cancer Antibody Drug Conjugates Sales Market Share in Value by Type in 2022
Figure 17. Latin America Cancer Antibody Drug Conjugates Sales Market Share in Volume by Type in 2022
Figure 18. Latin America Cancer Antibody Drug Conjugates Sales Market Share in Value by Type in 2022
Figure 19. Middle East and Africa Cancer Antibody Drug Conjugates Sales Market Share in Volume by Type in 2022
Figure 20. Middle East and Africa Cancer Antibody Drug Conjugates Sales Market Share in Value by Type in 2022
Figure 21. The 5 and 10 Largest Manufacturers in the World: Market Share by Cancer Antibody Drug Conjugates Sales in 2022
Figure 22. The 5 and 10 Largest Manufacturers in the World: Market Share by Cancer Antibody Drug Conjugates Revenue in 2022
Figure 23. Cancer Antibody Drug Conjugates Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 24. Product Picture of Hospitals
Figure 25. Global Hospitals Sales YoY Growth (2018-2034) & (K Dose)
Figure 26. Product Picture of Clinics
Figure 27. Global Clinics Sales YoY Growth (2018-2034) & (K Dose)
Figure 28. Product Picture of Others
Figure 29. Global Others Sales YoY Growth (2018-2034) & (K Dose)
Figure 30. Global Cancer Antibody Drug Conjugates Sales by Application (2018-2034) & (US$ Million)
Figure 31. Global Cancer Antibody Drug Conjugates Sales Market Share by Application in 2022 & 2034
Figure 32. North America Cancer Antibody Drug Conjugates Sales Market Share in Volume by Application in 2022
Figure 33. North America Cancer Antibody Drug Conjugates Sales Market Share in Value by Application in 2022
Figure 34. Europe Cancer Antibody Drug Conjugates Sales Market Share in Volume by Application in 2022
Figure 35. Europe Cancer Antibody Drug Conjugates Sales Market Share in Value by Application in 2022
Figure 36. Asia-Pacific Cancer Antibody Drug Conjugates Sales Market Share in Volume by Application in 2022
Figure 37. Asia-Pacific Cancer Antibody Drug Conjugates Sales Market Share in Value by Application in 2022
Figure 38. Latin America Cancer Antibody Drug Conjugates Sales Market Share in Volume by Application in 2022
Figure 39. Latin America Cancer Antibody Drug Conjugates Sales Market Share in Value by Application in 2022
Figure 40. Middle East and Africa Cancer Antibody Drug Conjugates Sales Market Share in Value by Application in 2022
Figure 41. Key Raw Materials Price
Figure 42. Cancer Antibody Drug Conjugates Manufacturing Cost Structure
Figure 43. Cancer Antibody Drug Conjugates Industrial Chain Analysis
Figure 44. Channels of Distribution
Figure 45. Distributors Profiles
Figure 46. Bottom-up and Top-down Approaches for This Report
Figure 47. Data Triangulation
Figure 48. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries